examined mutations in more than 50 genes (ALK, BRAF, EGFR, KRAS, MET, TP53, etc.)in patients with double primary lung cancer (n=40), which resulted in a match with the clinicopathological diagnosis in 82.5% (33/40) of patients (13). This evidence concerns the gene ALK and lung carcinoma.